SILIQ™ Product Monograph, Bausch Health, Canada Inc., June 7, 2019.
2.
GooderhamM, et al. IL-17-Targeteted therapies: adverse events of special interest. J Cutan Med Surg. 2017;21(Sup.2):21S-27S.
3.
CohenBE.MartiresKJ.HoRS. Psoriasis and the risk of depression in the US population: National health and nutrition examination survey 2009-2012. JAMA Dermatol. 2016;152(1):73-79.doi:10.1001/jamadermatol.2015.3605
4.
DalgardFJ.GielerU.Tomas-AragonesLet al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991.doi:10.1038/jid.2014.530
5.
KurdSK.TroxelAB.Crits-ChristophP.GelfandJM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-895.doi:10.1001/archdermatol.2010.186
6.
LebwohlMG.PappKA.MarangellLBet al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81-89.doi:10.1016/j.jaad.2017.08.024
7.
GooderhamM.Gavino-VelascoJ.CliffordCet al. A review of psoriasis, therapies, and suicide. J Cutan Med Surg. 2016;20(4):293-303.doi:10.1177/1203475416648323
8.
PappKA.ReichK.PaulCet al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273-286.doi:10.1111/bjd.14493
9.
StroberB.GooderhamM.de JongEMGJet al. Depressive symptoms, depression, and the effect of biologic therapy among patients in psoriasis longitudinal assessment and registry (PSOLAR). J Am Acad Dermatol. 2018;78(1):70-80.doi:10.1016/j.jaad.2017.08.051
